In development: Guidance, quality standards and advice
Showing 1 to 5 of 5
| Title | Type | Expected publication date |
|---|---|---|
| Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524] | Technology appraisal guidance | TBC |
| Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394] | Technology appraisal guidance | TBC |
| Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID6235 | Technology appraisal guidance | |
| Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547] | Technology appraisal guidance | TBC |
| Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID1237 | Technology appraisal guidance |